The identification of key oncogenic driver alterations in NSCLC has led to the development of tailored treatments. ROS1 rearrangements occur in 1% to 2% of NSCLC.1 Dysregulation of MNNG HOS Transforming gene (MET) signaling through MET exon 14 skipping mutations or MET amplification has been reported in 3% to 4% and 2% to 5% of adenocarcinomas, respectively.2 To our knowledge, co-alteration of c-MET and ROS1 or ALK tyrosine kinase receptor gene (ALK) have not been described yet and the optimal management of this clinical condition is unknown.

Rihawi K, C.M. (2018). Co-alteration of c-Met and ROS1 in Advanced NSCLC: ROS1 Wins. JOURNAL OF THORACIC ONCOLOGY, 13(3), 41-43 [10.1016/j.jtho.2017.10.024].

Co-alteration of c-Met and ROS1 in Advanced NSCLC: ROS1 Wins

Rihawi K;Fiorentino M;SALVAGNI, SANDRO;Brocchi S;Ardizzoni A
2018

Abstract

The identification of key oncogenic driver alterations in NSCLC has led to the development of tailored treatments. ROS1 rearrangements occur in 1% to 2% of NSCLC.1 Dysregulation of MNNG HOS Transforming gene (MET) signaling through MET exon 14 skipping mutations or MET amplification has been reported in 3% to 4% and 2% to 5% of adenocarcinomas, respectively.2 To our knowledge, co-alteration of c-MET and ROS1 or ALK tyrosine kinase receptor gene (ALK) have not been described yet and the optimal management of this clinical condition is unknown.
2018
Rihawi K, C.M. (2018). Co-alteration of c-Met and ROS1 in Advanced NSCLC: ROS1 Wins. JOURNAL OF THORACIC ONCOLOGY, 13(3), 41-43 [10.1016/j.jtho.2017.10.024].
Rihawi K, Cinausero M, Fiorentino M, Salvagni S, Brocchi S, Ardizzoni A
File in questo prodotto:
Eventuali allegati, non sono esposti

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11585/678771
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 4
  • ???jsp.display-item.citation.isi??? 3
social impact